BREAKING: Indexes Suffer Painful Week
A key decision from Eli Lilly (LLY) — possibly next week — could light up the obesity treatment landscape again, an analyst said Friday as LLY stock lingers near a record high.
All eyes have been on Lilly’s tirzepatide in obesity, but the company is also developing a next-generation approach to weight loss called retatrutide. While tirzepatide hits on two elements that can impact body weight, retatrutide loops in a third.
“We see a reasonable likelihood that Lilly will provide an update on retatrutide, its triple (obesity treatment regimen), on the 2023 guidance call,” UBS analyst Colin Bristow said in a note to clients. Lilly has scheduled that call for Tuesday morning.
Representatives of Eli Lilly didn’t immediately return a request for comment.
On today’s stock market, LLY stock sank 2.9% to close at 360.99.
Retatrutide works by stimulating three elements that could improve weight loss.
Lilly’s tirzepatide is already approved in diabetes treatment and sells under the name Mounjaro. It’s also in testing for obesity. It hits on the gastric inhibitory polypeptide receptor and the glucagon-like peptide-1 receptor — respectively, GIPR and GLP-1. In late-stage testing, tirzepatide recipients have lost up to 22.5% of their weight.
Retatrutide stimulates both GIPR and GLP-1, but it also adds in the glucagon receptor.
The company has said it expects to have midstage testing data for retatrutide before year end.
“We believe the update could come on Tuesday and if Lilly simply tells us it is moving forward to Phase 3, this is a major positive,” UBS analyst Bristow said. “Lilly had previously stated it will only move (retatrutide) forward if it shows differentiated (effectiveness) vs. Mounjaro (which we take to mean about 25% weight loss).”
Bristow has a buy rating on LLY stock and raised his price target to 428 from 407.
The obesity treatment space is gaining steam in late 2022.
Novo Nordisk (NVO) makes Wegovy, the only approved drug. But Wegovy is facing supply shortages. Lilly’s tirzepatide is nearing potential Food and Drug Administration approval, with retatrutide waiting in the wings. Amgen (AMGN) is also years behind with an experimental drug that recently led to speedy weight loss in Phase 1 testing.
All three stocks have soared recently. LLY stock broke out of a flat base with a buy point at 335.43 in late September, MarketSmith.com shows. Amgen stock hit a fresh high in November and Novo stock broke out of a consolidation with an entry at 122.26 late last month. Both Lilly and Novo stocks are now above their 5% chase zones.
The three also have strong Relative Strength Ratings, according to IBD Digital. LLY stock is in the lead with an RS Rating of 96 out of a best-possible 99. This means the stock ranks in the top 4% of all stocks in terms of 12-month performance. Amgen and Novo are rated 95 and 93, respectively.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MAY ALSO LIKE:
Why Mirati Therapeutics Stock Lost Half Its Value In Just Three Days
Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences
Find Today’s Best Growth Stocks To Watch With IBD 50
Get Timely Buy & Sell Alerts With IBD Leaderboard
Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists
12/09/2022 The best mutual funds scooped up shares of MRK, LLY, ABBV and AMGN, while also adding retailers like WING to…
12/09/2022 The best mutual funds scooped up shares of MRK, LLY,…
(© Gary Neill)
Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!
Get market updates, educational videos, webinars, and stock analysis.
Learn how you can make more money with IBD’s investing tools, top-performing stock lists, and educational content.
Notice: Information contained herein is not and should not be construed as an offer, solicitation, or recommendation to buy or sell securities. The information has been obtained from sources we believe to be reliable; however no guarantee is made or implied with respect to its accuracy, timeliness, or completeness. Authors may own the stocks they discuss. The information and content are subject to change without notice.
*Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.
Ownership data provided by Refinitiv and Estimates data provided by FactSet.
© 2000-2022 Investor’s Business Daily, LLC. All rights reserved
